-
1 Comment
Merrimack Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 2.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Merrimack Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 134.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.7% to $-2M since the same quarter in the previous year.
Based on the above factors, Merrimack Pharmaceuticals, Inc gets an overall score of 3/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US5903282094 |
| Exchange | NASDAQ |
| Industry | Biotechnology |
| Sector | Healthcare |
| Dividend Yield | 57.% |
|---|---|
| Beta | 1.86 |
| Market Cap | 182M |
| Target Price | 4 |
| PE Ratio | None |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MACK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
